Jacobs Levy Equity Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Jacobs Levy Equity Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-535,836	Closed	-$1.59M	–	1121
2022 Q1	$1.59M	Buy	535,836 +286,767	+115%	+$1.08M	0.01%	670
2021 Q4	$1.12M	Buy	249,069 +232,884	+1,439%	+$1.1M	0.01%	722
2021 Q3	$79K	Buy	+16,185	New	+$89.2K	﹤0.01%	1016
2021 Q2	–	Sell	-63,210	Closed	-$446K	–	1140
2021 Q1	$446K	Buy	63,210 +26,220	+71%	+$189K	﹤0.01%	873
2020 Q4	$232K	Buy	+36,990	New	+$218K	﹤0.01%	952
2018 Q3	–	Sell	-48,900	Closed	-$499K	–	1098
2018 Q2	$499K	Buy	48,900 +6,070	+14%	+$68.7K	0.01%	797
2018 Q1	$557K	Buy	42,830 +30,100	+236%	+$448K	0.01%	764
2017 Q4	$228K	Buy	+12,730	New	+$266K	﹤0.01%	881

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Jacobs Levy Equity Management's PRTK Position: Q2 2022 in Review

Jacobs Levy Equity Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 535,836 shares — an estimated $1.59M sold.

Jacobs Levy Equity Management first reported a position in PRTK in Q4 2017 and held it in 8 quarters. The position peaked at $1.59M in Q1 2022. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

Jacobs Levy Equity Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 535,836 Paratek Pharmaceuticals, Inc. shares in Q2 2022, an estimated $1.59M.
Jacobs Levy Equity Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2017 and held it in 8 quarters.
Jacobs Levy Equity Management's Paratek Pharmaceuticals, Inc. position peaked at $1.59M in Q1 2022.
84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2022, filed 15 Aug 2022.